张莎,伍杨,黄新苗,秦永文,赵仙先,白元

• 1:海军军医大学附属长海医院心血管内科

摘要(Abstract)：

随着左心耳封堵术在非瓣膜性心房颤动患者卒中预防中的应用逐年增多,心房颤动相关卒中的发生率明显下降。但值得关注的是,无论是在临床试验还是在临床实践中,均可观察到左心耳封堵术后卒中事件的发生。探究此类不良事件的发生规律有助于提升左心耳封堵术预防卒中的效果。本文通过复习相关文献,对左心耳封堵术后卒中事件发生的现状、卒中原因、预防措施进行综述。

关键词(KeyWords)： 左心耳封堵术;心房颤动;缺血性卒中

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目（81770506）;; 海军军医大学附属长海医院“234学科攀峰计划”（2020YXK010）

作者(Author): 张莎,伍杨,黄新苗,秦永文,赵仙先,白元

参考文献(References)：

• [1] Sievert H, Lesh M, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fi brillation:early clinical experience. Circulation,2002,105(16):1887-1889.
• [2] Boersma LV, Ince H, Kische S, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology:final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ Arrhythm Electrophysiol, 2019, 12(4):e006841.
• [3] Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol, 2017, 70(24):2964-2975.
• [4] Holmes DR Jr, Reddy VY, Gordon NT, et al. Long-term safety and e ffi cacy in continued access left atrial appendage closure registries. J Am Coll Cardiol, 2019, 74(23):2878-2889.
• [5] Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation:multicentre experience with the AMPLATZER cardiac plug. EuroIntervention, 2016, 11(10):1170-1179.
• [6] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fi brillation:a randomised non-inferiority trial.Lancet, 2009, 374(9689):534-542.
• [7] Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation:2.3-year follow-up of the PROTECT AF(Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation)trial. Circulation, 2013, 127(6):720-729.
• [8] Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fi brillation:a randomized clinical trial. JAMA, 2014, 312(19):1988-1998.
• [9] Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fi brillation versus long-term warfarin therapy:the PREVAIL trial. J Am Coll Cardiol, 2014, 64(1):1-12.
• [10] Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation:1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm, 2017, 14(9):1302-1308.
• [11] Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation:results from the international multi-center feasibility trials. J Am Coll Cardiol, 2005, 46(1):9-14.
• [12] Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fi brillation suboptimal for warfarin therapy:5-year results of the PLAATO(Percutaneous Left Atrial Appendage Transcatheter Occlusion)study. JACC Cardiovasc Interv, 2009, 2(7):594-600.
• [13] Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fi brillation. J Am Coll Cardiol, 2007, 49(13):1490-1495.
• [14] Freixa X, Llull L, Gafoor S, et al. Characterization of cerebrovascular events after left atrial appendage occlusion. Am J Cardiol, 2016, 118(12):1836-1841.
• [15] Tu HT, Campbell BC, Christensen S, et al. Pathophysiological determinants of worse stroke outcome in atrial f ibrillation.Cerebrovasc Dis, 2010, 30(4):389-395.
• [16] Lee OH, Kim YD, Kim JS, et al. Favorable neurological outcome after ischemic cerebrovascular events in patients treated with percutaneous left atrial appendage occlusion compared with warfarin.Catheter Cardiovasc Interv, 2019, 94(1):E23-E29.
• [17] Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fi brillation.J Am Coll Cardiol, 2018, 71(14):1528-1536.
• [18] Dukkipati S,Kar S,Holmes D,et al. Device-related thrombus after left atrial appendage closure:incidence, predictors,and outcomes.Circulation,2018, 138(9):874-885.
• [19] Bai Y, Xue X, Duenninger E, et al. Real-world survival data of device-related thrombus following left atrial appendage closure:4-year experience from a single center. Heart Vessels, 2019, 34(8):1360-1369.
• [20] Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs.noncardioembolic strokes in atrial fi brillation:frequency and eff ect of antithrombotic agents in the stroke prevention in atrial fi brillation studies. Cerebrovasc Dis, 2000, 10(1):39-43.
• [21] Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fi brillation. Cerebrovasc Dis,2002, 13(1):16-20.
• [22] Kim JS, Lee H, Suh Y, et al. Left atrial appendage occlusion in non-valvular atrial fi brillation in a Korean multi-center registry. Circ J, 2016, 80(5):1123-1130.
• [23] Cresti A, Garcia-Fernandez MA, Sievert H, et al. Prevalence of extraappendage thrombosis in non-valvular atrial fi brillation and atrial fl utter in patients undergoing cardioversion:a large transoesophageal echo study. EuroIntervention, 2019, 15(3):e225-e230.
• [24] Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure:assessment by transesophageal echocardiography. J Am Coll Cardiol, 2008, 52(11):924-929.
• [25] Sahore A, Della Rocca DG, Anannab A, et al. Clinical implications and management strategies for left atrial appendage leaks. Card Electrophysiol Clin, 2020, 12(1):89-96.
• [26] Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete:a transesophageal echocardiograhic study. J Am Coll Cardiol, 2000, 36(2):468-471.
• [27] Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fi brillation:a PROTECT AF(percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fi brillation)substudy. J Am Coll Cardiol, 2012, 59(10):923-929.
• [28] Saw J, Tzikas A, Shakir S, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug. JACC Cardiovasc Interv, 2017, 10(4):391-399.
• [29] Cochet H, Iriart X, Sridi S, et al. Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion:a computed tomography study. Eur Heart J Cardiovasc Imaging, 2018, 19(12):1351-1361.
• [30] Saw J, Nielsen-Kudsk JE, Bergmann M, et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. JACC Cardiovasc Interv, 2019, 12(11):1067-1076.
• [31] Raphael CE,Friedman PA,Saw J, et al. Residual leaks following percutaneous left atrial appendage occlusion:assessment and management implications. EuroIntervention,2017,13(10):1218-1225.
• [32] Tzikas A, Gafoor S, Meerkin D, et al. Left atrial appendage occlusion with the AMPLATZER amulet device:an expert consensus step-by-step approach. EuroIntervention, 2016, 11(13):1512-1521.